array:24 [ "pii" => "S0213005X17301210" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2017.03.003" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1682" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:229-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 9440 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 7728 "PDF" => 1710 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S2529993X18300480" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2018.02.012" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1682" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:229-32" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1744 "formatos" => array:2 [ "HTML" => 1066 "PDF" => 678 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief report</span>" "titulo" => "From CLSI to EUCAST guidelines in the interpretation of antimicrobial susceptibility: What is the effect in our setting?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "229" "paginaFinal" => "232" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Cambio de CLSI a EUCAST en la interpretación de la sensibilidad a antimicrobianos: ¿cómo influye en nuestro medio?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Antonia Sánchez-Bautista, Javier Coy, Patricia García-Shimizu, Juan Carlos Rodríguez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Antonia" "apellidos" => "Sánchez-Bautista" ] 1 => array:2 [ "nombre" => "Javier" "apellidos" => "Coy" ] 2 => array:2 [ "nombre" => "Patricia" "apellidos" => "García-Shimizu" ] 3 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Rodríguez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213005X17301210" "doi" => "10.1016/j.eimc.2017.03.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17301210?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18300480?idApp=UINPBA00004N" "url" => "/2529993X/0000003600000004/v2_201804060412/S2529993X18300480/v2_201804060412/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S0213005X18300016" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2018.01.001" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1806" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:233-40" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3627 "formatos" => array:2 [ "HTML" => 2441 "PDF" => 1186 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Formación Médica Continuada: Infecciones por micobacterias</span>" "titulo" => "Epidemiología molecular de la tuberculosis" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "233" "paginaFinal" => "240" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Molecular epidemiology of tuberculosis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pere Coll, Darío García de Viedma" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Pere" "apellidos" => "Coll" ] 1 => array:2 [ "nombre" => "Darío" "apellidos" => "García de Viedma" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X18300686" "doi" => "10.1016/j.eimce.2018.01.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18300686?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X18300016?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000004/v1_201804040507/S0213005X18300016/v1_201804040507/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0213005X17300964" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2017.02.002" "estado" => "S300" "fechaPublicacion" => "2018-04-01" "aid" => "1672" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:225-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 2906 "formatos" => array:3 [ "EPUB" => 3 "HTML" => 2425 "PDF" => 478 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original breve</span>" "titulo" => "Bacteriemia por <span class="elsevierStyleItalic">Clostridium perfringens</span>. Un análisis de 28 casos durante 10 años en un hospital universitario de Madrid" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "225" "paginaFinal" => "228" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "<span class="elsevierStyleItalic">Clostridium perfringens</span> bacteraemia, an analysis of 28 cases over 10 years in a university hospital of Madrid" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.ª Fátima Lopez-Fabal, Nuria Sanz, Mario Ruiz-Bastian, Carlos Barros, Jose-Luis Gomez-Garces" "autores" => array:5 [ 0 => array:2 [ "nombre" => "M.ª Fátima" "apellidos" => "Lopez-Fabal" ] 1 => array:2 [ "nombre" => "Nuria" "apellidos" => "Sanz" ] 2 => array:2 [ "nombre" => "Mario" "apellidos" => "Ruiz-Bastian" ] 3 => array:2 [ "nombre" => "Carlos" "apellidos" => "Barros" ] 4 => array:2 [ "nombre" => "Jose-Luis" "apellidos" => "Gomez-Garces" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X18300479" "doi" => "10.1016/j.eimce.2018.02.011" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18300479?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17300964?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000004/v1_201804040507/S0213005X17300964/v1_201804040507/es/main.assets" ] "es" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original breve</span>" "titulo" => "Cambio de CLSI a EUCAST en la interpretación de la sensibilidad a antimicrobianos: ¿cómo influye en nuestro medio?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "229" "paginaFinal" => "232" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Antonia Sánchez-Bautista, Javier Coy, Patricia García-Shimizu, Juan Carlos Rodríguez" "autores" => array:4 [ 0 => array:3 [ "nombre" => "Antonia" "apellidos" => "Sánchez-Bautista" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "Javier" "apellidos" => "Coy" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Patricia" "apellidos" => "García-Shimizu" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:4 [ "nombre" => "Juan Carlos" "apellidos" => "Rodríguez" "email" => array:1 [ 0 => "rodriguez_juadia@gva.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Microbiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Microbiología, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "From CLSI to EUCAST guidelines in the interpretation of antimicrobial susceptibility: What is the effect in our setting?" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introducción</span><p id="par0005" class="elsevierStylePara elsevierViewall">La resistencia antibiótica es un grave problema de salud pública, cuyo abordaje exige un trabajo multidisciplinar. Uno de los pilares básicos es el tratamiento empírico adecuado de los pacientes con base en los datos de la epidemiología local<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">1</span></a>. Gracias al trabajo del Comité Español del Antibiograma (COESANT), entre los hospitales españoles hay una clara tendencia a sustituir la normativa del comité norteamericano <span class="elsevierStyleItalic">Clinical and Laboratory Standards Institute</span> (CLSI) por la establecida por el <span class="elsevierStyleItalic">European Committee on Antimicrobial Susceptibility Testing</span> (EUCAST) a la hora de interpretar los datos aportados por los estudios de sensibilidad antibacteriana. Nuestro estudio pretende comparar los cambios de las tasas de resistencia que origina esta modificación en nuestro medio.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material y métodos</span><p id="par0010" class="elsevierStylePara elsevierViewall">Se analizan los patrones de sensibilidad de 10.359 aislados clínicos (primer aislado de cada paciente) de <span class="elsevierStyleItalic">Escherichia coli</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>4.987)<span class="elsevierStyleItalic">, Klebsiella pneumoniae</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.324)<span class="elsevierStyleItalic">, Pseudomonas aeruginosa</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.159)<span class="elsevierStyleItalic">, Staphylococcus aureus</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.066)<span class="elsevierStyleItalic">, Enterococcus faecalis</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.522) y <span class="elsevierStyleItalic">Enterococcus faecium</span> (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>301), aislados durante un período de 17 meses en el Hospital General Universitario de Alicante (pacientes hospitalizados y atención primaria) mediante ambos criterios. Los valores de concentración mínima inhibitoria se estudiaron por el método de microdilución comercial (MicroScan WalkAway 96 Plus, Siemens, Alemania) y se compararon los porcentajes de sensibilidad obtenidos según los puntos de corte del CLSI y el EUCAST (2017) mediante el sistema informático Microb Dynamic (Soria Melguizo, España).</p><p id="par0015" class="elsevierStylePara elsevierViewall">Para comparar los resultados se utilizó el índice <span class="elsevierStyleItalic">kappa</span>.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Resultados</span><p id="par0020" class="elsevierStylePara elsevierViewall">Los criterios de interpretación para la mayoría de las combinaciones microorganismo-antibiótico fueron iguales por ambos criterios. En las enterobacterias, el cambio de criterio no supuso un cambio en los datos de sensibilidad para varios antimicrobianos. Así, para <span class="elsevierStyleItalic">Escherichia coli/Klebsiella pneumoniae</span> los porcentajes de sensibilidad por ambos criterios fueron: ampicilina (43,3-0%), cefotaxima (87,8-77,9%) y trimetoprim-sulfametoxazol (68,3-86,5%); en <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> fueron: cefepima (82,3%), ceftazidima (86,8%), meropenem (78,9%), piperacilina (70,9%), piperacilina/tazobactam (84,5%), ticarcilina (43,9%) y tobramicina (88,7%); en <span class="elsevierStyleItalic">Staphylococcus aureus</span> los porcentajes de sensibilidad fueron: ciprofloxacino (90,8%), daptomicina (100%), levofloxacino (91,9%), linezolid (100%), oxacilina (84,9%), trimetoprim-sulfametoxazol (99,1%) y vancomicina (100%), y en <span class="elsevierStyleItalic">Enterococcus</span> spp., el cambio no produjo variaciones en el porcentaje de sensibilidad a la vancomicina (100%). No fue posible evaluar la actividad de amoxicilina/ácido clavulánico ya que la concentración de ácido clavulánico recomendada por los 2 comités es diferente. En otras combinaciones antibiótico-microorganismo se observaron algunas diferencias que pueden tener trascendencia clínica. La comparación de estos datos se detalla en la <a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">El fenómeno más destacado es que la aplicación del EUCAST originó una disminución importante de la sensibilidad a los aminoglucósidos (gentamicina y amicacina), tanto en enterobacterias (3,7 puntos en <span class="elsevierStyleItalic">Escherichia coli</span> y 5,3 puntos en <span class="elsevierStyleItalic">Klebsiella pneumoniae</span> para amicacina) como en <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> (23,2 puntos para el mismo antibiótico). No obstante, la gran mayoría de estos aislados no llegaron a ser completamente resistentes, ya que los porcentajes de resistencia a amicacina se elevaron mucho menos: <span class="elsevierStyleItalic">Escherichia coli</span> (0,4%), <span class="elsevierStyleItalic">Klebsiella pneumoniae</span> (1,6%) y <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> (5,7%).</p><p id="par0030" class="elsevierStylePara elsevierViewall">En relación con la actividad de la fosfomicina, la aplicación del EUCAST originó un incremento de la resistencia en <span class="elsevierStyleItalic">Escherichia coli</span> (2,1%) y en <span class="elsevierStyleItalic">Klebsiella pneumoniae</span> (10,9%).</p><p id="par0035" class="elsevierStylePara elsevierViewall">El porcentaje de cepas sensibles a las fluoroquinolonas en enterobacterias presentó una escasa variación, pero en el caso de <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span>, la aplicación del EUCAST supuso una disminución de la sensibilidad a estos antimicrobianos de forma importante (8,2%). El porcentaje de cepas de <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> sensibles a aztreonam también disminuyó notablemente (64,1%).</p><p id="par0040" class="elsevierStylePara elsevierViewall">En <span class="elsevierStyleItalic">Staphylococcus aureus</span> es muy destacable la disminución de la sensibilidad a la gentamicina (43,1%) y a la tobramicina (37,9%), fenómeno que también se observó para la clindamicina (51,5%). En cuanto a la sensibilidad de <span class="elsevierStyleItalic">Enterococcus</span> spp., se observaron cambios mucho menos marcados excepto para ciprofloxacino, que supuso un 100% de sensibilidad al aplicar los criterios del EUCAST.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Discusión</span><p id="par0045" class="elsevierStylePara elsevierViewall">Una de las principales aportaciones de la Microbiología Clínica a la mejora del tratamiento de los procesos infecciosos, además del diagnóstico rápido y correcto de los mismos, es el estudio de la epidemiología local de la resistencia antibiótica, pieza angular de los protocolos locales de terapia empírica<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">2</span></a>. Estos datos han cobrado mucha más importancia con el incremento de la multirresistencia, lo que exige un análisis riguroso y exhaustivo de los mismos<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">3,4</span></a>.</p><p id="par0050" class="elsevierStylePara elsevierViewall">La incorporación paulatina de los criterios del EUCAST en los hospitales europeos está obligando a evaluar la repercusión clínica de este cambio en cada entorno geográfico<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">5,6</span></a>. En general, los cambios en las tasas de resistencia aplicando los 2 criterios son pequeños en nuestro medio, por lo que el cambio de normas no tiene por qué alterar de forma significativa la política de antibióticos del hospital. Estos cambios reflejan la complejidad de la resistencia antibiótica, en especial de los mecanismos que originan bajos niveles de resistencia a los antimicrobianos<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">7</span></a>.</p><p id="par0055" class="elsevierStylePara elsevierViewall">Sin embargo, el cambio que puede tener un mayor impacto clínico al aplicar los criterios del EUCAST es la reducción de las tasas de sensibilidad de <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> a la amicacina, que podría obligar a replantear la asociación de este antibiótico a los carbapenémicos como tratamiento empírico de infecciones graves con sospecha de este patógeno. Sin embargo, hay que tener en cuenta que la mayor parte de los aislados no llegan a encuadrarse en la categoría de resistentes, por lo que habrá que evaluar la terapia más adecuada cuando estén implicadas cepas con estas características<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">8</span></a>. En relación con los carbapenémicos, las diferencias de puntos de corte al aplicar ambos criterios no varían y no suponen una trascendencia clínica en nuestro medio ni en el caso de enterobacterias ni en <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span><a class="elsevierStyleCrossRefs" href="#bib0120"><span class="elsevierStyleSup">9,10</span></a>.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Otro hecho destacable es la disminución de los porcentajes de sensibilidad a fosfomicina en enterobacterias y en <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span>. Este hecho puede ser más importante en el futuro porque cada vez aumenta más la necesidad de utilizar este antimicrobiano en tratamientos empíricos de infecciones producidas por cepas multirresistentes<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">11,12</span></a>.</p><p id="par0065" class="elsevierStylePara elsevierViewall">En relación con la disminución de los porcentajes de sensibilidad a clindamicina en <span class="elsevierStyleItalic">Staphylococcus aureus</span> también puede obligar a revisar algunas terapias empíricas, especialmente en el tratamiento de infecciones de piel y partes blandas, en las que este fármaco es uno de los considerados como de elección.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Es recomendable el cambio a los criterios del EUCAST, pero las modificaciones en los porcentajes de sensibilidad que origina deben ser analizadas de forma conjunta por todos los especialistas implicados en el manejo de la enfermedad infecciosa, ya que las variaciones que pueden aparecer en la epidemiología local de la resistencia pueden tener repercusiones clínicas en la práctica asistencial<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">13–15</span></a>.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Financiación</span><p id="par0075" class="elsevierStylePara elsevierViewall">Este trabajo ha sido realizado gracias a la ayuda de la Fundación Soria Melguizo y a la Fundación FISABIO (UGP-14-270).</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Conflicto de intereses</span><p id="par0080" class="elsevierStylePara elsevierViewall">Los autores declaran que no tienen ningún conflicto de intereses.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1011703" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusiones" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec970970" "titulo" => "Palabras clave" ] 2 => array:3 [ "identificador" => "xres1011704" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusions" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec970969" "titulo" => "Keywords" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introducción" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Material y métodos" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Resultados" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discusión" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Financiación" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Conflicto de intereses" ] 10 => array:1 [ "titulo" => "Bibliografía" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-09-25" "fechaAceptado" => "2017-03-24" "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec970970" "palabras" => array:3 [ 0 => "CLSI" 1 => "EUCAST" 2 => "Resistencia antibiótica" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec970969" "palabras" => array:3 [ 0 => "CLSI" 1 => "EUCAST" 2 => "Antimicrobial resistance" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introducción</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">La aplicación de los puntos de corte establecidos por el <span class="elsevierStyleItalic">European Committee on Antimicrobial Susceptibility Testing</span> (EUCAST) en comparación con los del <span class="elsevierStyleItalic">Clinical and Laboratory Standards Institute</span> (CLSI) modifica los criterios de interpretación de la sensibilidad de algunos antimicrobianos y esto conduce a cambios en los informes de sensibilidad antibiótica acumulada.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Métodos</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Análisis de la influencia de la aplicación del EUCAST en 10.359 aislados clínicos de <span class="elsevierStyleItalic">Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus</span> y <span class="elsevierStyleItalic">Enterococcus</span> spp.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Resultados</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Al aplicar los puntos de corte del EUCAST, la mayoría de los porcentajes de sensibilidad a antimicrobianos no se alteró o lo hizo de forma muy leve; sin embargo, se observó una disminución de la sensibilidad a los aminoglucósidos en bacilos gramnegativos, especialmente a la amicacina en <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> (23,2%), aunque solo el 5,7% fueron totalmente resistentes; además, disminuyó notablemente el porcentaje de aislados sensibles a aztreonam. Es de destacar el aumento de cepas de <span class="elsevierStyleItalic">Staphylococcus aureus</span> resistentes a clindamicina (51,5%) y a aminoglucósidos (gentamicina 43,1%).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusiones</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El cambio de los criterios del CLSI a los de EUCAST en algunos patógenos supone una alteración en los porcentajes de resistencia a algunos antimicrobianos y, por tanto, en la epidemiología local de la resistencia. Estos cambios deben realizarse por un grupo multidisciplinar, que analice la influencia de los nuevos datos en los protocolos de tratamiento empírico de cada centro.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusiones" ] ] ] "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introduction</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Implementation of the breakpoints established in the <span class="elsevierStyleItalic">European Committee on Antimicrobial Susceptibility Testing</span> (EUCAST) guidelines in comparison with those of the <span class="elsevierStyleItalic">Clinical and Laboratory Standards Institute</span> (CLSI) means that the criteria for interpreting the susceptibility of some antimicrobials have been modified, resulting in changes in the reports of accumulated antibiotic susceptibility.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Methods</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The effect of applying EUCAST breakpoints in 10,359 clinical isolates of <span class="elsevierStyleItalic">Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa</span>, <span class="elsevierStyleItalic">Staphylococcus aureus</span> and <span class="elsevierStyleItalic">Enterococcus</span> spp. was analysed.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Results</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">By applying EUCAST breakpoints, most antimicrobial susceptibility percentages did not change or changed very slightly. However, a decrease in aminoglycoside susceptibility was observed in Gram-negative bacilli, mainly for amikacin and <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> (23.2%), although only 5.7% were completely resistant; a notably decrease in the percentage of isolates susceptible to aztreonam was also observed. There was also a marked increase in the number of <span class="elsevierStyleItalic">Staphylococcus aureus</span> strains resistant to clindamycin (51.5%) and aminoglycosides (gentamicin 43.1%).</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusions</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Switching from CLSI to EUCAST criteria in some pathogens alters the percentages of resistance to several antimicrobials, and therefore the local epidemiology of the resistance. These changes should be implemented by a multidisciplinary group in order to analyse the influence of the new data on the empirical treatment protocols of each centre.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusions" ] ] ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Tabla 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Tabla " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">IC<span class="elsevierStyleInf">95</span>: intervalo de confianza del 95%; κ: índice kappa.</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Se señala entre paréntesis el valor de la concentración mínima inhibitoria considerado como sensible por los diferentes criterios.</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Para los microorganismos gramnegativos, CLSI solo admite el punto de corte de fosfomicina para aislados urinarios y en infecciones urinarias no complicadas para enterobacterias. No hay punto de corte para <span class="elsevierStyleItalic">Pseudomonas</span> spp. en ninguno de los comités.</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Para los microorganismos grampositivos, los puntos de corte para las 2 quinolonas en <span class="elsevierStyleItalic">Enterococcus</span> spp. son solo para aislados urinarios.</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Entre paréntesis se indican los puntos de corte de sensibilidad establecidos por el CLSI y por el EUCAST.</p>" "tablatextoimagen" => array:2 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="5" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Antimicrobianos</th><th class="td" title="table-head " colspan="8" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Microorganismos gramnegativos</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Escherichia coli</span></th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Klebsiella pneumoniae</span></th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Pseudomonas aeruginosa</span></th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="4" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>4.987)</th><th class="td" title="table-head " colspan="4" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.324)</th><th class="td" title="table-head " colspan="4" align="left" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.159)</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC<span class="elsevierStyleInf">95</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC<span class="elsevierStyleInf">95</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC<span class="elsevierStyleInf">95</span> \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Amicacina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 99,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 95,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,27 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,20-0,34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 98,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 92,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,38 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,27-0,49 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 90,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 67,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,36 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,30-0,41 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Aztreonam \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 72,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 8,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,07 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,05-0,08 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ceftazidima \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 97,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 95,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,70 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,64-0,75 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 96,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 94,1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,72 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,63-0,81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ciprofloxacino \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 72,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤0,25) 70,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,93 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,92-0,94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 88,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,25) 86,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,91 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,88-0,95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 75,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 67,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,76-0,84 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Colistina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 97,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 98,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,71-0,91 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Fosfomicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>64) 87,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>32) 85,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,91 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,89-0,93 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>64) 78,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>32) 67,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,73 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,69-0,77 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Gentamicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 89,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 84,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,80 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,78-0,82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 4) 93,1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 91,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,90 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,86-0,95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Imipenem \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 99,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 99,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,39-0,94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 97,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 97,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,93 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,86-0,99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 81,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 85,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,84 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,80-0,88 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Levofloxacino \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 67,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 67,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,98-0,99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 79,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 76,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,91 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,89-0,94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 73,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 63,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,78 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,75-0,82 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Meropenem \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 99,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 99,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,53 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,39-0,67 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 85,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 86,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,98 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,96-0,99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Norfloxacino \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 74,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 54,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,58 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,56-0,60 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 89,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 0,5) 69,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,37-0,46 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Piperacilina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 40,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 37,8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,94-0,95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 30,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 22,1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,78 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,74-0,82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Piperacilina/tazobactam \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 16) 94,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 92,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,78-0,84 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>16) 91,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 87,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,82 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,77-0,87 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tobramicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 88,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 83,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,79 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,76-0,81 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 4) 92,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 91,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,90 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,86-0,94 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1713359.png" ] ] 1 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " colspan="5" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Antibiótico</th><th class="td" title="table-head " colspan="8" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Microorganismos grampositivos</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Staphylococcus aureus</span></th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Enterococcus faecium</span></th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">Enterococcus faecalis</span></th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.066)</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>301)</th><th class="td" title="table-head " colspan="4" align="center" valign="top" scope="col" style="border-bottom: 2px solid black">(N° de cepas<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>1.522)</th></tr><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC95 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC95 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">CLSI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">EUCAST \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">κ \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IC95 \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ampicilina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 14,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 11,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,866 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,78-0,95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 8) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 99,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,00-0,00 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Ciprofloxacino \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,00-0,00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 1) 58,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,00-0,00 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Clindamicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 95,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,25) 44,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,07 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,05-0,09 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Eritromicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>0,5) 76,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 77,7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,98 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,96-0,99 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Gentamicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 94,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 51,5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,09-0,14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Levofloxacino \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 15,3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 23,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,75 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,65-0,84 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 65,4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 66,6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,97 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,96-0,98 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Linezolid \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Teicoplanina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 8) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 99,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,00-0,00 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>2) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>8) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 2) 100 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tetraciclinas \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span> 4) 94,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 86,2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,57 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,49-0,65 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Tobramicina \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>4) 90,9 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">(≤<span class="elsevierStyleHsp" style=""></span>1) 53,0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,20 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0,17-0,24 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1713358.png" ] ] ] ] "descripcion" => array:1 [ "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Comparación de los porcentajes de sensibilidad a antimicrobianos de microorganismos gramnegativos y de los porcentajes de sensibilidad antibiótica en bacterias grampositivas según criterios del CLSI y del EUCAST</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:15 [ 0 => array:3 [ "identificador" => "bib0080" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of clinical categories for <span class="elsevierStyleItalic">Escherichia coli</span> harboring specific qnr and chromosomal-mediated fluoroquinolone resistance determinants according to CLSI and EUCAST" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J. Machuca" 1 => "A. Briales" 2 => "P. Díaz-de-Alba" 3 => "L. Martínez-Martínez" 4 => "J.M. Rodríguez-Martínez" 5 => "Á.A. Pascual" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2015.01.019" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin." "fecha" => "2016" "volumen" => "34" "paginaInicial" => "188" "paginaFinal" => "190" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25772329" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0085" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "IDSA: Better, faster diagnostics for infectious diseases needed to curb overtreatment, antibiotic resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "B.M. Kuehn" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jama.2013.283828" "Revista" => array:7 [ "tituloSerie" => "JAMA." "fecha" => "2013" "volumen" => "310" "paginaInicial" => "2385" "paginaFinal" => "2386" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24327022" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1473309913702573" "estado" => "S300" "issn" => "14733099" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0090" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M. Ciccolini" 1 => "V. Spoorenberg" 2 => "S.E. Geerlings" 3 => "J.M. Prins" 4 => "H. Grundmann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/jac/dku336" "Revista" => array:6 [ "tituloSerie" => "J Antimicrob Chemother." "fecha" => "2015" "volumen" => "70" "paginaInicial" => "286" "paginaFinal" => "293" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25164311" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0095" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibiotic resistance in <span class="elsevierStyleItalic">Pseudomonas aeruginosa</span> and alternative therapeutic options" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Chatterjee" 1 => "C.P. Anju" 2 => "L. Biswas" 3 => "V. Anil Kumar" 4 => "C. Gopi Mohan" 5 => "R. Biswas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ijmm.2015.11.004" "Revista" => array:6 [ "tituloSerie" => "Int J Med Microbiol." "fecha" => "2016" "volumen" => "306" "paginaInicial" => "48" "paginaFinal" => "58" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26687205" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0100" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: Influence on cumulative hospital antibiograms" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Wolfensberger" 1 => "H. Sax" 2 => "R. Weber" 3 => "R. Zbinden" 4 => "S.P. Kuster" 5 => "M. Hombach" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1371/journal.pone.0079130" "Revista" => array:5 [ "tituloSerie" => "PLoS One." "fecha" => "2013" "volumen" => "8" "paginaInicial" => "e79130" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24223893" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0105" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Hombach" 1 => "A. Wolfensberger" 2 => "S.P. Kuster" 3 => "E.C. Böttger" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/JCM.00921-13" "Revista" => array:6 [ "tituloSerie" => "J Clin Microbiol." "fecha" => "2013" "volumen" => "51" "paginaInicial" => "2385" "paginaFinal" => "2387" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23596246" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0110" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidelines" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M. Hombach" 1 => "E.C. Böttger" 2 => "M. Roos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/1469-0691.12090" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect." "fecha" => "2013" "volumen" => "19" "paginaInicial" => "E59" "paginaFinal" => "E71" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23210931" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0115" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Optimizing antibiotic dosing strategies for the treatment of Gram-negative infections in the era of resistance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.L. Monogue" 1 => "J.L. Kuti" 2 => "D.P. Nicolau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/17512433.2016.1133286" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Clin Pharmacol." "fecha" => "2016" "volumen" => "9" "paginaInicial" => "459" "paginaFinal" => "476" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26678036" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0120" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Breakpoints for carbapenemase-producing Enterobacteriaceae: Is the problem solved?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Cantón" 1 => "A. Canut" 2 => "M.I. Morosini" 3 => "A. Oliver" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0213-005X(14)70172-7" "Revista" => array:7 [ "tituloSerie" => "Enferm Infecc Microbiol Clin." "fecha" => "2014" "volumen" => "32" "numero" => "Suppl 4" "paginaInicial" => "33" "paginaFinal" => "40" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25542050" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0125" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carbapenem susceptibility breakpoints, clinical implications with the moving target" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.N. O’Donnell" 1 => "C.M. Miglis" 2 => "J.Y. Lee" 3 => "M. Tuvell" 4 => "T. Lertharakul" 5 => "M.H. Scheetz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14787210.2016.1159131" "Revista" => array:6 [ "tituloSerie" => "Expert Rev Anti Infect Ther." "fecha" => "2016" "volumen" => "14" "paginaInicial" => "389" "paginaFinal" => "401" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26918486" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0130" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L.V. Perdigão-Neto" 1 => "M.S. Oliveira" 2 => "C.F. Rizek" 3 => "C.M. Carrilho" 4 => "S.F. Costa" 5 => "A.S. Levin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.02048-13" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother." "fecha" => "2014" "volumen" => "58" "paginaInicial" => "1763" "paginaFinal" => "1767" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24323469" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0135" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Carbapenemase-producing Klebsiella pneumoniae: A key pathogen set for global nosocomial dominance" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J.D. Pitout" 1 => "P. Nordmann" 2 => "L. Poirel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.01019-15" "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother." "fecha" => "2015" "volumen" => "59" "paginaInicial" => "5873" "paginaFinal" => "5884" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26169401" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0140" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of CLSI breakpoint changes on microbiology laboratories and antimicrobial stewardship programs" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "E.L. Heil" 1 => "J.K. Johnson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/JCM.02424-15" "Revista" => array:6 [ "tituloSerie" => "J Clin Microbiol." "fecha" => "2016" "volumen" => "54" "paginaInicial" => "840" "paginaFinal" => "844" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26791363" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0145" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antimicrobial susceptibility cumulative reports" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Canut-Blasco" 1 => "J. Calvo" 2 => "J.C. Rodríguez-Díaz" 3 => "L. Martínez-Martínez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2015.03.019" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin." "fecha" => "2016" "volumen" => "34" "paginaInicial" => "524" "paginaFinal" => "530" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25962661" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0150" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Development of a national EUCAST challenge panel for antimicrobial susceptibility testing" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Desmet" 1 => "J. Verhaegen" 2 => "Y. Glupzcynski" 3 => "J. van Eldere" 4 => "P. Melin" 5 => "H. Goossens" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2016.05.011" "Revista" => array:7 [ "tituloSerie" => "Clin Microbiol Infect." "fecha" => "2016" "volumen" => "22" "paginaInicial" => "704" "paginaFinal" => "710" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27234934" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0140673609609181" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/0213005X/0000003600000004/v1_201804040507/S0213005X17301210/v1_201804040507/es/main.assets" "Apartado" => array:4 [ "identificador" => "8593" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Originales breves" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/0213005X/0000003600000004/v1_201804040507/S0213005X17301210/v1_201804040507/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17301210?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Original breve
Cambio de CLSI a EUCAST en la interpretación de la sensibilidad a antimicrobianos: ¿cómo influye en nuestro medio?
From CLSI to EUCAST guidelines in the interpretation of antimicrobial susceptibility: What is the effect in our setting?
Antonia Sánchez-Bautistaa, Javier Coya, Patricia García-Shimizub, Juan Carlos Rodríguezc,
Autor para correspondencia
a Servicio de Microbiología, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España
b Servicio de Medicina Preventiva, Hospital General Universitario de Alicante, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España
c Servicio de Microbiología, Hospital General Universitario de Alicante, Universidad Miguel Hernández, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL-Fundación FISABIO), Alicante, España